Obesity-Hypoventilation Syndrome

OHS is associated with hospitalizations for acute-on-chronic hypercapnic respiratory failure and with chronic heart failure and pulmonary hypertension. In a patient with severe obesity and suspected ventilatory failure, obtain an arterial blood gas promptly to establish PaCO2 and PaO2, then determine whether the presentation represents previously unrecognized chronic hypercapnia or acute deterioration on chronic respiratory failure. clinicaltrialsclinicaltrialsStudy Details | NCT07147153 | Functional Capacity, Sleep Quality, and Cognitive Function in Obesity Hypoventilation Syndrome | ClinicalTrials.gov

Review immediately reversible ventilatory depressants. Opioids, including transdermal buprenorphine, can dangerously decrease pulmonary ventilation, especially when combined with other respiratory depressants. Risk is amplified by severe obesity, sleep apnea, hypoxia, hypercapnia, COPD or cor pulmonale, and pre-existing respiratory depression; profound sedation, unresponsiveness, infrequent deep breaths, atypical snoring, and respiratory distress are warning findings. accessdata fdaaccessdata fdaCENTER FOR DRUG EVALUATION AND ... - accessdata.fda.gov

Use noninvasive ventilatory support when OHS is accompanied by chronic respiratory failure or when acute hypercapnic decompensation requires ventilatory assistance; NIV is an effective treatment modality in OHS. Once stabilized, transition to a formal sleep-disordered-breathing and daytime gas-exchange assessment rather than labeling the patient as having isolated obstructive sleep apnea. BMJ+1BMJNon-invasive ventilation in obesity hypoventilation ...clinicaltrialsStudy Details | NCT07147153 | Functional Capacity, Sleep Quality, and Cognitive Function in Obesity Hypoventilation Syndrome | ClinicalTrials.gov

Establish OHS when all three elements are present: BMI at least 30 kg/m², awake PaCO2 greater than 45 mm Hg, and no alternative pathology that explains hypoventilation. The threshold is expressed as PaCO2 at least 45 mm Hg in consensus definitions and greater than 45 mm Hg in other diagnostic descriptions; clinically, a daytime PaCO2 of 45 mm Hg or higher should trigger assessment for OHS when obesity is present. Wiley+2WileyInternational Consensus Statement on Obstructive Sleep ...Wolters KluwerObesity hypoventilation syndromeclinicaltrialsStudy Details | NCT07147153 | Functional Capacity, Sleep Quality, and Cognitive Function in Obesity Hypoventilation Syndrome | ClinicalTrials.gov

Use serum bicarbonate as a screening discriminator rather than a diagnostic substitute. A bicarbonate threshold of 27 mmol/L is used to select patients for arterial blood-gas analysis; confirm suspected OHS with an ABG because the syndrome is defined by awake arterial hypercapnia. ScienceDirect+1ScienceDirectSleep disordered breathing assessment in patient with ...Wolters KluwerObesity hypoventilation syndrome

Do not diagnose OHS until alternate causes of hypoventilation have been considered. The defining exclusion is other pathology causing hypoventilation; specifically assess whether COPD or another chronic lung disorder, neuromuscular or chest-wall disease, medication-related CNS depression, or another cause better accounts for daytime CO2 retention. Severe obesity, sleep apnea, hypoxia, hypercapnia, CNS depression, and clinically significant kyphoscoliosis can coexist and increase vulnerability to respiratory depression, but coexistence does not eliminate the need to determine the dominant cause of hypoventilation. accessdata fda+2accessdata fdaCENTER FOR DRUG EVALUATION AND ... - accessdata.fda.govWolters KluwerObesity hypoventilation syndromeclinicaltrialsStudy Details | NCT07147153 | Functional Capacity, Sleep Quality, and Cognitive Function in Obesity Hypoventilation Syndrome | ClinicalTrials.gov

Perform formal assessment for sleep-disordered breathing after confirming or strongly suspecting obesity-related daytime hypercapnia. OHS is defined in contemporary descriptions by obesity, awake hypercapnia, absence of alternate causes, and sleep-disordered breathing; however, about 10% of patients with OHS do not have obstructive sleep apnea. ccjm+1ccjmNoninvasive positive pressure ventilation for stable ...clinicaltrialsStudy Details | NCT07147153 | Functional Capacity, Sleep Quality, and Cognitive Function in Obesity Hypoventilation Syndrome | ClinicalTrials.gov

When obstructive sleep apnea is present, use positive-airway-pressure titration to eliminate apneas and hypopneas. CPAP titration in OHS has been directed at eliminating obstructive respiratory events, but response must include reassessment of nocturnal oxygenation and daytime gas exchange because approximately 40% of patients with OHS have persistent nocturnal hypoxemia and daytime hypercapnia after CPAP eliminates sleep apnea. ccjm+1ccjmNoninvasive positive pressure ventilation for stable ...journal chestnetPositive Airway Pressure Titration in Obesity Hypoventilation ...

Persistent hypercapnia or hypoxemia after adequate obstruction control is a management branch, not simply a reason to raise CPAP pressure. It indicates that contributors other than upper-airway obstruction remain clinically relevant and supports reassessment for noninvasive ventilation. BMJ+1BMJNon-invasive ventilation in obesity hypoventilation ...ccjmNoninvasive positive pressure ventilation for stable ...

Use positive-airway-pressure treatment in confirmed OHS. Randomized trials have compared CPAP with NIV as initial therapy, and NIV is an effective treatment for OHS with chronic respiratory failure. The practical distinction is whether CPAP eliminates the clinically relevant obstructive component while restoring gas exchange, versus whether ongoing hypoventilation requires pressure support ventilation. BMJ+1BMJNon-invasive ventilation in obesity hypoventilation ...journal chestnetObesity Hypoventilation Syndrome : Chest

Select CPAP when obstructive sleep apnea is the dominant treatable sleep finding and use titration directed at eliminating apneas and hypopneas. Do not equate successful event control with successful OHS treatment: persistent nocturnal hypoxemia or daytime hypercapnia after CPAP is documented in about 40% of affected patients and should prompt a switch in the clinical question from airway patency to ventilation. ccjm+1ccjmNoninvasive positive pressure ventilation for stable ...journal chestnetPositive Airway Pressure Titration in Obesity Hypoventilation ...

Use NIV when chronic respiratory failure is present, when obstructive sleep apnea is absent, or when CPAP adequately controls obstructive events but gas exchange remains abnormal. Published trials include pressure-support and volume-targeted approaches, but NIV titration may be suboptimal if sleep transcutaneous CO2 is not used; therefore, pair device follow-up with objective CO2 and oxygenation reassessment when available. BMJ+3BMJNon-invasive ventilation in obesity hypoventilation ...ccjmNoninvasive positive pressure ventilation for stable ...journal chestnetLong-term Noninvasive Ventilation in Obesity Hypoventilation ...clinicaltrialsStudy Details | NCT06047405 | NIV for Hypercapnic Respiratory Failure: AVAPS vs S/T BIPAP | ClinicalTrials.gov

Avoid iatrogenic ventilatory suppression during long-term management. Opioids can produce respiratory depression, and the labeling specifically identifies sleep apnea, severe obesity, hypoxia, hypercapnia, COPD or cor pulmonale, and CNS depression as high-risk states. Before escalating sedatives or opioids, verify the patient’s current ventilatory status and PAP adherence. accessdata fdaaccessdata fdaCENTER FOR DRUG EVALUATION AND ... - accessdata.fda.gov

At follow-up, compare daytime PaCO2 with the pretreatment ABG and assess nocturnal oxygenation after PAP initiation or adjustment. This is essential because OHS can retain daytime hypercapnia and nocturnal hypoxemia after CPAP has eliminated obstructive sleep apnea. ccjm+1ccjmNoninvasive positive pressure ventilation for stable ...journal chestnetPositive Airway Pressure Titration in Obesity Hypoventilation ...

Use sleep transcutaneous CO2, when available, to guide NIV optimization because absent transcutaneous CO2-based titration has been identified as a potential source of suboptimal NIV titration. Persistent CO2 elevation despite apparent device success should trigger review of delivered ventilation, adherence, sleep-disordered-breathing phenotype, opioid or sedative exposure, and competing causes of hypoventilation. accessdata fda+1accessdata fdaCENTER FOR DRUG EVALUATION AND ... - accessdata.fda.govjournal chestnetLong-term Noninvasive Ventilation in Obesity Hypoventilation ...

Reassess after major clinical change, including acute hypercapnic hospitalization, increased opioid exposure, or substantial weight loss. OHS is associated with recurrent acute-on-chronic hypercapnic respiratory failure, while postoperative improvement in sleep-related oxygen desaturation after Roux-en-Y weight loss does not establish that ventilatory support can be withdrawn without repeat testing. BMJ+1BMJPoster PresentationsclinicaltrialsStudy Details | NCT07147153 | Functional Capacity, Sleep Quality, and Cognitive Function in Obesity Hypoventilation Syndrome | ClinicalTrials.gov